Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010)

To evaluate the efficacy, safety, and tolerability of 10 mg/kg intravenous efgartigimod administered in a fixed-cycle regimen (4 once-weekly infusions with a 4-week intertreatment period) or continuous dosing regimen (every 2 weeks).